Skip to main content
. 2020 Feb;222(2):157.e1–157.e13. doi: 10.1016/j.ajog.2019.08.008

Table 3.

Sociodemographic and biological correlates of metronidazole treatment successa

OR (95% CI)b P valueb
Sociodemographic correlates
Age (continuous variable) 1.06 (0.97–1.17) .186
Education level
 Primary school not completedc 1.23 (0.26–5.90) .795
 Primary school completedc 1.80 (0.31–10.5) .514
 Secondary school not completedc 0.33 (0.02–4.74) .417
Exchanged sex for money/goods in month prior to posttreatment visit 5.40 (0.56–52.08) .145
Used a condom at the last vaginal sex act prior to posttreatment visit 0.99 (0.97–1.02) .678
Condom use in the 2 weeks prior to posttreatment visit
 Always vs never 0.36 (0.03–3.92) .399
 Sometimes (but not always) vs never 0.22 (0.02–2.19) .196
Currently using hormonal contraception at the posttreatment visit 0.69 (0.23–2.05) .499
Currently breastfeeding at the posttreatment visit 1.00 (0.97–1.03) .874
Inserted anything in vagina in the 12 months prior to posttreatment visit 1.03 (0.34–3.10) .959
Had menses in 7 days prior to posttreatment visit 1.83 (0.41–8.23) .429
Reported any urogenital symptoms at the pretreatment visit 0.67 (0.21–2.11) .496
Reported any urogenital symptoms at the posttreatment visit NAd NAd
Biological correlates (at pretreatment visit)
 Total lactobacilli concentration 1.14 (0.80–1.62) .476
 Total BV-anaerobes concentration 0.79 (0.41–1.53) .489
 Total pathobionts concentration 0.76 (0.58–0.99) .044
 Total other bacteria concentration 0.83 (0.63–1.10) .191
 Gardnerella vaginalis concentratione 0.86 (0.44–1.65) .640
 Atopobium vaginae concentrationf 0.83 (0.59–1.17) .285
 Prevotella concentration 0.93 (0.65–1.33) .691
 Sneathia concentration 0.86 (0.63–1.16) .318
 Megasphaera concentration 1.12 (0.89–1.42) .333
 Veillonella concentration 0.85 (0.68–1.06) .157
 BVAB1 concentration 1.01 (0.83–1.23) .912
 Fusobacterium concentration 0.89 (0.61–1.30) .549
Vaginal microbiota type
 LA vs Li 1.75 (0.10–30.84) .702
 BV_GV vs Li 0.46 (0.04–5.75) .550
 BV_noGV vs Li 0.67 (0.04–11.29) .779
 GV vs Li 0.30 (0.02–4.91) .398
 BV_GV vs LA 0.27 (0.05–1.52) .136
 BV_noGV vs LA 0.38 (0.04–3.34) .383
 GV vs LA 0.17 (0.02–1.44) .104
Pooled vaginal microbiota type
 LA vs Lactobacillus-dominated [Li or Lo] 1.75 (0.10–30.84) 0.702
 [BV_GV or BV_noGV or GV] vs Lactobacillus-dominated [Li or Lo] 0.45 (0.04–5.40) 0.532
Yeasts on wet mount 0.83 (0.05–13.9) 0.896
Trichomonas vaginalis on wet mount 1.71 (0.15–20.1) 0.661
Positive urinalysis test 1.22 (0.33–4.44) 0.765
Any bacterial sexually transmitted infection (CT/NG/syphilis) 0.65 (0.22–1.91) 0.435
Positive herpes simplex virus type 2 serology 2.16 (0.70–6.69) 0.178

BV, bacterial vaginosis; BVAB1, BV-associated bacterium type 1; BV_GV, polybacterial Gardnerella vaginalis-containing; BV_noGV, polybacterial but low G. vaginalis; CI, confidence interval; CT, Chlamydia trachomatis; GV, G. vaginalis-dominated; LA, lactobacilli and anaerobes; Li, L. iners-dominated; Lo, other lactobacilli-dominated; NA, not applicable; NG, Neisseria gonorrhoeae; OR, odds ratio.

Verwijs et al. Impact of oral metronidazole treatment on the vaginal microbiota and correlates of treatment failure. Am J Obstet Gynecol 2020.

a

Successful treatment defined as Nugent 7–10 pre- and 0–3 posttreatment (n=30 women) and treatment failure as Nugent 7–10 pre and 4–10 posttreatment (n=25 women)

b

Bivariable logistic regression models

c

Compared with no schooling

d

No women reported urogenital symptoms at the posttreatment visit

e

Includes reads assigned to Gardnerella genus

f

Includes reads assigned to Atopobium genus.